Spark Therapeutics (ONCE) : The money flow analysis of Spark Therapeutics (ONCE) indicates a $10.92 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $14.54 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.33 and so was the total money flow at $3.62 million. The bulls lapped up $1.04 million worth of block trades on upticks. The money flow was $1.04 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Spark Therapeutics (ONCE), pushing it down by -0.5% for the day. The stock slid $0.29 and traded at $57.26 during the day. Nonetheless, the stock is 4.55% over the previous weeks close.
The company Insiders own 9.6% of Spark Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -25.28% . Institutional Investors own 78.79% of Spark Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -25.47%.
In a related news, The Securities and Exchange Commission has divulged that ChildrenS Hospital Of Philade, director 10% owner of Spark Therapeutics, Inc., had unloaded 1,000,000 shares at an average price of $60.9 in a transaction dated on August 16, 2016. The total value of the transaction was worth $60,900,000.
Spark Therapeutics (NASDAQ:ONCE): The stock opened at $59.28 and touched an intraday high of $60.0737 on Friday. During the day, the stock corrected to an intraday low of $57.2, however, the bulls stepped in and pushed the price higher to close in the green at $58.14 with a gain of 1.03% for the day. The total traded volume for the day was 935,877. The stock had closed at $57.55 in the previous trading session.
Spark Therapeutics (ONCE) has been under a strong bear grip, hence the stock is down -2.42% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 5.62% in the past 1 week. The stock has risen by 6.15% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.55% in the past 4 weeks.
Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. Sparks product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs, including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Companys product development portfolio includes product candidates targeting expression of genes in the liver, with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.